Literature DB >> 17880950

A comparison study of a novel stimulation protocol and the conventional low dose step-up and step-down regimens in patients with polycystic ovary syndrome undergoing in vitro fertilization.

Savvas N Koundouros1.   

Abstract

OBJECTIVE: To compare the efficacy of a sequential step-up/step-down protocol with the conventional low dose step-up and the step-down regimens in patients with polycystic ovary syndrome (PCOS) undergoing IVF.
DESIGN: Prospective randomized study.
SETTING: Private fertility clinic. PATIENT(S): Two hundred twenty-five, 30-year-old or younger, women with PCOS. INTERVENTION(S): The low dose step-up, the step-down, and a sequential step-up/step-down regimens were used. MAIN OUTCOME MEASURE(S): Ovarian response, pregnancy (PR) and miscarriage rate. RESULT(S): Patients in group A (low dose step-up) exhibited the highest cancellation rate, whereas subjects in group C (sequential regimen) the lowest. The hormonal dosage (ampules) and duration of stimulation (days) was higher in group A patients and lower in group B (step-down regimen). The follicular growth uniformity was superior in group C patients who also achieved a higher number of eggs at retrieval, better fertilization and embryo development rates. The sequential group yielded the highest pregnancy and the lowest miscarriage rate. CONCLUSION(S): The sequential step-up/step-down stimulation protocol is superior to the low dose step-up and step-down regimens with regard to ovarian response, PR and miscarriage rate in 30-year-old or younger patients with PCOS undergoing IVF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17880950     DOI: 10.1016/j.fertnstert.2007.06.080

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  1 in total

1.  Step-Down of FSH- Dosage During Ovarian Stimulation - Basic Lessons to Be Learnt From a Randomized Controlled Trial.

Authors:  Barbara Lawrenz; Carol Coughlan; Laura Melado; Shieryl Digma; Junard Sibal; Alliza Jean; Human M Fatemi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-13       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.